FY 2025 Results
Ipsen’s financial results for the full year 2025 will be published on 12 February 2026.
An investor and analyst conference will take place on the same day.
The latest highlights from Investor Relations
Find out what’s been happening at Ipsen Investor Relations lately – including financial results, announcements, IR events, and more.
12 February 2026
FY 2025 Results
31 July 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
10 April 2025
Q1 2025 sales update
13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…
12 January 2025
J.P. Morgan Healthcare Conference
Investing for growth
We see everyone within the Ipsen investor community as a valued stakeholder who helps drive our overall success. Dedicated to transparency and ethical decision-making, we aim to provide investors with the resources they need to understand our company and how we plan to reach our ambitious targets.
Underpinned by a robust balance sheet and strong cash generation, we have the ambition to replenish our pipeline. With a successful strategy, we’re proud to be backed by an investor community that recognizes our positive progress.
Ipsen’s latest investor presentation
Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Please find below Ipsen’s latest investor presentation, reflecting our most recent messaging and key updates on strategy, performance and pipeline.
Strong results backed by innovation
With total sales growth of over 9%*, we delivered strong results in 2024, and we’ve had a strong start to 2025. We are on track to build further momentum in our transformation, and to achieve our objectives for the year. *At constant exchange rate.
Download Ipsen’s Annual ReportInvestor events
Ipsen is dedicated to providing investors with the tools they need to understand our company and goals. Our events offer investors the opportunity to meet our management and investor-relations teams and learn more about our strategy.
Pipeline
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across our three therapeutic areas of Oncology, Rare Disease and Neuroscience.
Shareholder information
We aim to transparently communicate to our investor community our analyst coverage, ADR program and shareholding structure.
Learn more
Regulated information
Information on voting rights updates, combined shareholders’ meeting and our share buyback program. View the publications and press releases related to regulated information.
Learn moreFive-year stock information
Share price and stock information, benchmark, orders, transactions: discover the data related to Ipsen’s shares.
Your dedicated contacts
Henry Wheeler
Vice President, Investor Relations
Khalid Deojee
Senior Manager, Investor Relations